CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 53,835	$ 39,545
Short-term marketable securities	46,140	62,881
Receivables from collaborative arrangements	14,664	17,474
Prepaid clinical and development services	2,086	2,038
Other prepaid and current assets	7,569	11,603
Total current assets	124,294	133,541
Property and equipment, net	8,717	9,068
Operating lease assets	35,364	36,287
Future contingent milestone and royalty assets	194,200	194,200
Restricted cash	836	836
Other assets	7,896	8,067
Total assets	371,307	381,999
Current liabilities:
Accounts payable	1,686	1,524
Accrued personnel-related expenses	4,475	6,443
Accrued clinical and development expenses	1,399	2,246
Accrued general and administrative expenses	2,476	2,900
Operating lease liabilities	4,063	3,923
Tenant improvement payable to subleasee	6,490	6,490
Other accrued liabilities	1,073	1,241
Total current liabilities	21,662	24,767
Long-term operating lease liabilities	43,840	45,236
Future royalty payment contingency	28,417	27,788
Unrecognized tax benefits	67,075	65,294
Other long-term liabilities	5,445	5,919
Commitments and contingencies (Note 10)
Shareholders' Equity
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value per share: 200,000 shares authorized; 48,566 and 48,091 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Additional paid-in capital	1,125,677	1,122,164
Accumulated other comprehensive loss	(41)	(65)
Accumulated deficit	(920,768)	(909,104)
Total shareholders' equity	204,868	212,995
Total liabilities and shareholders' equity	$ 371,307	$ 381,999